共 174 条
[1]
Stensballe LG(2003)Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus Pediatr Infect Dis J 22 S21-32
[2]
Devasundaram JK(1988)Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies J Virol 62 4232-4238
[3]
Simoes EA(1989)Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function J Virol 63 2941-2950
[4]
Anderson LJ(1989)Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins J Virol 63 925-932
[5]
Bingham P(1987)Respiratory syncytial virus fusion glycoprotein: further characterization of a major epitope involved in virus neutralization Can J Microbiol 33 933-938
[6]
Hierholzer JC(1997)Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus J Infect Dis 176 1215-1224
[7]
Beeler JA(2003)Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease J Pediatr 143 532-540
[8]
van Wyke Coelingh K(2004)Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants J Infect Dis 190 975-978
[9]
Garcia-Barreno B(2007)Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract J Mol Biol 368 652-665
[10]
Palomo C(2006)In vitro and in vivo fitness of respiratory syncytial virus monoclonal antibody escape mutants J Virol 80 11651-11657